60 related articles for article (PubMed ID: 35384730)
1. Validation of a French Version of the Mystical Experience Questionnaire with Retrospective Reports of the Most Significant Psychedelic Experience among French Users.
Fauvel B; Kangaslampi S; Strika-Bruneau L; Roméo B; Piolino P
J Psychoactive Drugs; 2023; 55(2):170-179. PubMed ID: 35384730
[TBL] [Abstract][Full Text] [Related]
2. Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.
Barrett FS; Johnson MW; Griffiths RR
J Psychopharmacol; 2015 Nov; 29(11):1182-90. PubMed ID: 26442957
[TBL] [Abstract][Full Text] [Related]
3. The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies.
Stocker K; Hartmann M; Ley L; Becker AM; Holze F; Liechti ME
J Psychopharmacol; 2024 Jan; 38(1):80-100. PubMed ID: 37905369
[TBL] [Abstract][Full Text] [Related]
4. Development of the Japanese version of the 30-item Mystical Experience Questionnaire.
Yonezawa K; Tani H; Nakajima S; Uchida H
Neuropsychopharmacol Rep; 2024 Mar; 44(1):280-284. PubMed ID: 37704433
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting subjective effects of LSD in normal subjects.
Schmid Y; Liechti ME
Psychopharmacology (Berl); 2018 Feb; 235(2):535-545. PubMed ID: 28918441
[TBL] [Abstract][Full Text] [Related]
6. Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.
Barrett FS; Griffiths RR
Curr Top Behav Neurosci; 2018; 36():393-430. PubMed ID: 28401522
[TBL] [Abstract][Full Text] [Related]
7. Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.
Griffiths RR; Johnson MW; Richards WA; Richards BD; McCann U; Jesse R
Psychopharmacology (Berl); 2011 Dec; 218(4):649-65. PubMed ID: 21674151
[TBL] [Abstract][Full Text] [Related]
8. Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan.
Carbonaro TM; Johnson MW; Griffiths RR
Psychopharmacology (Berl); 2020 Aug; 237(8):2293-2304. PubMed ID: 32500212
[TBL] [Abstract][Full Text] [Related]
9. Clarifying and measuring the characteristics of experiences that involve a loss of self or a dissolution of its boundaries.
Canby NK; Lindahl J; Britton WB; Córdova JV
Conscious Cogn; 2024 Mar; 119():103655. PubMed ID: 38346364
[TBL] [Abstract][Full Text] [Related]
10. Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey.
Garcia-Romeu A; Davis AK; Erowid E; Erowid F; Griffiths RR; Johnson MW
Front Psychiatry; 2019; 10():955. PubMed ID: 32038317
[TBL] [Abstract][Full Text] [Related]
11. Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.
Davis AK; Barrett FS; Griffiths RR
J Contextual Behav Sci; 2020 Jan; 15():39-45. PubMed ID: 32864325
[TBL] [Abstract][Full Text] [Related]
12. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.
MacLean KA; Johnson MW; Griffiths RR
J Psychopharmacol; 2011 Nov; 25(11):1453-61. PubMed ID: 21956378
[TBL] [Abstract][Full Text] [Related]
13. Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study.
Barbut Siva J; Barba T; Kettner H; Kuc J; Nutt DJ; Carhart-Harris R; Erritzoe D
J Psychopharmacol; 2024 Feb; 38(2):145-155. PubMed ID: 38281075
[TBL] [Abstract][Full Text] [Related]
14. Naturalism and the hard problem of mysticism in psychedelic science.
Jylkkä J
Front Psychol; 2024; 15():1112103. PubMed ID: 38558777
[TBL] [Abstract][Full Text] [Related]
15. Psychedelic Communitas: Intersubjective Experience During Psychedelic Group Sessions Predicts Enduring Changes in Psychological Wellbeing and Social Connectedness.
Kettner H; Rosas FE; Timmermann C; Kärtner L; Carhart-Harris RL; Roseman L
Front Pharmacol; 2021; 12():623985. PubMed ID: 33995022
[No Abstract] [Full Text] [Related]
16. Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects.
Aday JS; Davis AK; Mitzkovitz CM; Bloesch EK; Davoli CC
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):424-435. PubMed ID: 33860172
[TBL] [Abstract][Full Text] [Related]
17. Developing a Direct Observation Measure of Therapeutic Connection in Psilocybin-Assisted Therapy: A Feasibility Study.
Gramling R; Bennett E; Curtis K; Richards W; Rizzo DM; Arnoldy F; Hegg L; Porter J; Honstein H; Pratt S; Tarbi E; Reblin M; Thambi P; Agrawal M
J Palliat Med; 2023 Dec; 26(12):1702-1708. PubMed ID: 37590474
[No Abstract] [Full Text] [Related]
18. Working with Weirdness: A Response to "Moving Past Mysticism in Psychedelic Science".
Breeksema JJ; van Elk M
ACS Pharmacol Transl Sci; 2021 Aug; 4(4):1471-1474. PubMed ID: 34423279
[TBL] [Abstract][Full Text] [Related]
19. Expanding the scope of "trans-humanism": situating within the framework of life and death education - the importance of a "trans-mystical mindset".
Phan HP; Ngu BH; Hsu CS; Chen SC; Wu L
Front Psychol; 2024; 15():1380665. PubMed ID: 38721316
[No Abstract] [Full Text] [Related]
20. Editorial: Down the rabbit hole - the psychological and neural mechanisms of psychedelic compounds and their use in treating mental health and medical conditions.
Peled-Avron L; Aday JS; Kalafateli AL; Hamilton HK; Woolley JD
Front Psychiatry; 2024; 15():1431389. PubMed ID: 38915850
[No Abstract] [Full Text] [Related]
[Next] [New Search]
